Multivitamin supplement use and risk of breast cancer: A meta-analysis

El uso de suplementos multivitamínicos y el riesgo de cáncer de seno: Un meta análisis

Translated title of the contribution: Multivitamin supplement use and risk of breast cancer: A meta-analysis

Agnes L F Chan, Henry W C Leung, Shiao Fung Wang

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

BACKGROUND: The association between consumption of multivitamins and breast cancer is inconsistent in epidemiologic studies. OBJECTIVE: To perform a meta-analysis of cohort and case-control studies to evaluate multivitamin intake and its relationship with breast cancer risk. METHODS: The published literature was systematically searched and reviewed using MEDLINE (1950 through July 2010), EMBASE (1980 through July 2010), and the Cochrane Central Register of Controlled Trials (The Cochrane Library 2010 issue 1). Studies that included specific risk estimates were pooled using a random-effects model. The bias and quality of these studies were assessed with REVMAN statistical software (version 5.0) and the GRADE method of the Cochrane Collaboration. RESULTS: Eight of 27 studies that included 355,080 subjects were available for analysis. The total duration of multivitamin use in these trials ranged from 3 to 10 years. The frequency of current use in these studies ranged from 2 to 6 times/ week. In analyses by duration of use 10 years or longer or 3 years or longer and by frequency 7 or more times/week that were reported in these studies, multivitamin use was not significantly associated with the risk of breast cancer. Only 1 recent Swedish cohort study concluded that multivitamin use is associated with an increased risk of breast cancer. The results of a meta-analysis that pooled data from 5 cohort studies and 3 case-control studies indicated that the overall multivariable relative risk and odds ratio were 0.10 (95% CI 0.60 to 1.63; p = 0.98) and 1.00 (95% CI 0.51 to 1.00; p = 1.00), respectively. The association was not statistically significant. CONCLUSIONS: Multivitamin use is likely not associated with a significant increased or decreased risk of breast cancer, but these results highlight the need for more case-control studies or randomized controlled clinical trials to further examine this relationship.

Original languageSpanish
Pages (from-to)476-484
Number of pages9
JournalAnnals of Pharmacotherapy
Volume45
Issue number4
DOIs
Publication statusPublished - Apr 2011

Fingerprint

Meta-Analysis
Breast Neoplasms
Case-Control Studies
Odds Ratio
Cohort Studies
MEDLINE
Libraries
Epidemiologic Studies
Software
Randomized Controlled Trials

Keywords

  • Breast cancer
  • Meta-analysis
  • Multivitamin supplements

ASJC Scopus subject areas

  • Pharmacology (medical)

Cite this

Multivitamin supplement use and risk of breast cancer: A meta-analysis : El uso de suplementos multivitamínicos y el riesgo de cáncer de seno: Un meta análisis. / Chan, Agnes L F; Leung, Henry W C; Wang, Shiao Fung.

In: Annals of Pharmacotherapy, Vol. 45, No. 4, 04.2011, p. 476-484.

Research output: Contribution to journalArticle

@article{42c5365173d54199b039f62e5a5efd73,
title = "Multivitamin supplement use and risk of breast cancer: A meta-analysis: El uso de suplementos multivitam{\'i}nicos y el riesgo de c{\'a}ncer de seno: Un meta an{\'a}lisis",
abstract = "BACKGROUND: The association between consumption of multivitamins and breast cancer is inconsistent in epidemiologic studies. OBJECTIVE: To perform a meta-analysis of cohort and case-control studies to evaluate multivitamin intake and its relationship with breast cancer risk. METHODS: The published literature was systematically searched and reviewed using MEDLINE (1950 through July 2010), EMBASE (1980 through July 2010), and the Cochrane Central Register of Controlled Trials (The Cochrane Library 2010 issue 1). Studies that included specific risk estimates were pooled using a random-effects model. The bias and quality of these studies were assessed with REVMAN statistical software (version 5.0) and the GRADE method of the Cochrane Collaboration. RESULTS: Eight of 27 studies that included 355,080 subjects were available for analysis. The total duration of multivitamin use in these trials ranged from 3 to 10 years. The frequency of current use in these studies ranged from 2 to 6 times/ week. In analyses by duration of use 10 years or longer or 3 years or longer and by frequency 7 or more times/week that were reported in these studies, multivitamin use was not significantly associated with the risk of breast cancer. Only 1 recent Swedish cohort study concluded that multivitamin use is associated with an increased risk of breast cancer. The results of a meta-analysis that pooled data from 5 cohort studies and 3 case-control studies indicated that the overall multivariable relative risk and odds ratio were 0.10 (95{\%} CI 0.60 to 1.63; p = 0.98) and 1.00 (95{\%} CI 0.51 to 1.00; p = 1.00), respectively. The association was not statistically significant. CONCLUSIONS: Multivitamin use is likely not associated with a significant increased or decreased risk of breast cancer, but these results highlight the need for more case-control studies or randomized controlled clinical trials to further examine this relationship.",
keywords = "Breast cancer, Meta-analysis, Multivitamin supplements",
author = "Chan, {Agnes L F} and Leung, {Henry W C} and Wang, {Shiao Fung}",
year = "2011",
month = "4",
doi = "10.1345/aph.1P445",
language = "西班牙语",
volume = "45",
pages = "476--484",
journal = "Annals of Pharmacotherapy",
issn = "1060-0280",
publisher = "Harvey Whitney Books Company",
number = "4",

}

TY - JOUR

T1 - Multivitamin supplement use and risk of breast cancer: A meta-analysis

T2 - El uso de suplementos multivitamínicos y el riesgo de cáncer de seno: Un meta análisis

AU - Chan, Agnes L F

AU - Leung, Henry W C

AU - Wang, Shiao Fung

PY - 2011/4

Y1 - 2011/4

N2 - BACKGROUND: The association between consumption of multivitamins and breast cancer is inconsistent in epidemiologic studies. OBJECTIVE: To perform a meta-analysis of cohort and case-control studies to evaluate multivitamin intake and its relationship with breast cancer risk. METHODS: The published literature was systematically searched and reviewed using MEDLINE (1950 through July 2010), EMBASE (1980 through July 2010), and the Cochrane Central Register of Controlled Trials (The Cochrane Library 2010 issue 1). Studies that included specific risk estimates were pooled using a random-effects model. The bias and quality of these studies were assessed with REVMAN statistical software (version 5.0) and the GRADE method of the Cochrane Collaboration. RESULTS: Eight of 27 studies that included 355,080 subjects were available for analysis. The total duration of multivitamin use in these trials ranged from 3 to 10 years. The frequency of current use in these studies ranged from 2 to 6 times/ week. In analyses by duration of use 10 years or longer or 3 years or longer and by frequency 7 or more times/week that were reported in these studies, multivitamin use was not significantly associated with the risk of breast cancer. Only 1 recent Swedish cohort study concluded that multivitamin use is associated with an increased risk of breast cancer. The results of a meta-analysis that pooled data from 5 cohort studies and 3 case-control studies indicated that the overall multivariable relative risk and odds ratio were 0.10 (95% CI 0.60 to 1.63; p = 0.98) and 1.00 (95% CI 0.51 to 1.00; p = 1.00), respectively. The association was not statistically significant. CONCLUSIONS: Multivitamin use is likely not associated with a significant increased or decreased risk of breast cancer, but these results highlight the need for more case-control studies or randomized controlled clinical trials to further examine this relationship.

AB - BACKGROUND: The association between consumption of multivitamins and breast cancer is inconsistent in epidemiologic studies. OBJECTIVE: To perform a meta-analysis of cohort and case-control studies to evaluate multivitamin intake and its relationship with breast cancer risk. METHODS: The published literature was systematically searched and reviewed using MEDLINE (1950 through July 2010), EMBASE (1980 through July 2010), and the Cochrane Central Register of Controlled Trials (The Cochrane Library 2010 issue 1). Studies that included specific risk estimates were pooled using a random-effects model. The bias and quality of these studies were assessed with REVMAN statistical software (version 5.0) and the GRADE method of the Cochrane Collaboration. RESULTS: Eight of 27 studies that included 355,080 subjects were available for analysis. The total duration of multivitamin use in these trials ranged from 3 to 10 years. The frequency of current use in these studies ranged from 2 to 6 times/ week. In analyses by duration of use 10 years or longer or 3 years or longer and by frequency 7 or more times/week that were reported in these studies, multivitamin use was not significantly associated with the risk of breast cancer. Only 1 recent Swedish cohort study concluded that multivitamin use is associated with an increased risk of breast cancer. The results of a meta-analysis that pooled data from 5 cohort studies and 3 case-control studies indicated that the overall multivariable relative risk and odds ratio were 0.10 (95% CI 0.60 to 1.63; p = 0.98) and 1.00 (95% CI 0.51 to 1.00; p = 1.00), respectively. The association was not statistically significant. CONCLUSIONS: Multivitamin use is likely not associated with a significant increased or decreased risk of breast cancer, but these results highlight the need for more case-control studies or randomized controlled clinical trials to further examine this relationship.

KW - Breast cancer

KW - Meta-analysis

KW - Multivitamin supplements

UR - http://www.scopus.com/inward/record.url?scp=79955611141&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79955611141&partnerID=8YFLogxK

U2 - 10.1345/aph.1P445

DO - 10.1345/aph.1P445

M3 - 文章

VL - 45

SP - 476

EP - 484

JO - Annals of Pharmacotherapy

JF - Annals of Pharmacotherapy

SN - 1060-0280

IS - 4

ER -